Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant lymphoma, lymphoblastic.

B N Nathwani, H Kim, H Rappaport

    Cancer
    |August 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Malignant lymphoma, lymphoblastic type (MLLB) comprises immature lymphoid cells similar to acute lymphoblastic leukemia (ALL). Recognizing MLLB is crucial for timely systemic therapy, even before hematologic progression is evident.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.

    Nature communications·2014
    Same author

    Fecal microbiota diversity in survivors of adolescent/young adult Hodgkin lymphoma: a study of twins.

    British journal of cancer·2013
    Same author

    Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification.

    Leukemia & lymphoma·2002
    Same author

    Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

    Annals of oncology : official journal of the European Society for Medical Oncology·2002
    Same author

    Hyperplasia of mantle/marginal zone B cells with clear cytoplasm in peripheral lymph nodes. A clinicopathologic study of 35 cases.

    American journal of clinical pathology·2001
    Same author

    Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with acquired immunodeficiency syndrome-related lymphoma.

    Blood·2001
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    Same journal

    Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

    Cancer·2026
    Same journal

    Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

    Cancer·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Pathology

    Background:

    • Malignant lymphomas of the diffuse, poorly differentiated lymphocytic type include a distinct subtype.
    • This subtype is characterized by immature lymphoid cells resembling those in acute lymphoblastic leukemia (ALL).

    Purpose of the Study:

    • To describe the clinicopathologic features of malignant lymphoma, lymphoblastic type (MLLB).
    • To emphasize the importance of morphologic recognition for treatment decisions.

    Main Methods:

    • Cytologic and morphologic analysis of lymphoid cells.
    • Clinical feature assessment including age, presentation, and disease progression.
    • Histologic and cytologic characterization focusing on nuclear morphology and mitotic index.

    Related Experiment Videos

    Main Results:

    • MLLB exhibits immature lymphoid cells indistinguishable from ALL lymphoblasts and prolymphocytes.
    • Common features include pediatric/adolescent occurrence, mediastinal masses (50%), high bone marrow/blood involvement, and rapid progression (median survival 8 months).
    • Nuclear convolutions are helpful but not essential for diagnosis; a high mitotic index is characteristic.

    Conclusions:

    • MLLB is a clinicopathologic entity characterized by immature lymphoid cells and high mitotic activity.
    • Early morphologic recognition is vital due to the frequent progression to ALL, potentially necessitating systemic therapy.
    • Diagnosis should not be solely based on nuclear convolution, patient age, or site of presentation.